Page last checked
Reconstitution · AOD-9604
Pick the vial, the water you added and the dose. Get the exact draw in units for the syringe in your hand.
Step 1 of 4
This vial holds 5 mg in total.
U-100 insulin syringe · 1 mL · lines every 2 units · 1 unit = 0.01 mL
60.0 units on a U-100 insulin syringe · 1 mL · lines every 2 units, which is 0.60 milliliters. The draw lands on a syringe line.
Your address is used to send this one card. The email also includes an optional link for updates when our data changes. Nothing else is sent unless you choose that link, and you can unsubscribe anytime.
AOD-9604 is the tail end of human growth hormone — residues 176 to 191, with one extra amino acid added on the front. It is sold for fat loss, on the idea that this fragment carries the hormone’s fat-mobilizing part and leaves the rest behind.
That idea was tested properly and it did not hold. An Australian company ran controlled human obesity trials, the larger ones did not separate it from placebo on weight, and development stopped there. The 10 mg group lost less than the 1 mg group, and the doses were swallowed rather than injected.
Each row starts with the same 5 mg vial and changes only the amount of water. More water makes the mixture less concentrated, so the same dose uses more syringe units.
| Water added | Concentration | Per U-100 unit | Draw for 1 mg | Nearest syringe line |
|---|---|---|---|---|
| 2 mL | 2.50 mg/mL | 25.0 mcg | 40.0 u · 0.400 mL | exactly 40 u |
| 3 mL | 1.67 mg/mL | 16.7 mcg | 60.0 u · 0.600 mL | exactly 60 u |
The vial, water and dose shown here are the calculator’s starting example for AOD-9604. Replace them with your own values. Every result in the table is calculated from those inputs.
Every controlled human study of this fragment gave it by mouth. Nothing published injected it. So there is no injected amount for this page to convert — only an oral one that does not carry across.
The trials ran for twelve weeks with participants swallowing a daily amount. Anything taken by mouth has to survive the gut and a first pass through the liver. Nothing published bridges what is left to what a syringe delivers.
That is why this page marks those figures as reported rather than studied. The number exists. The route it belongs to is not this one.
In those trials the larger group lost less weight than the smaller one. The bigger trials did not separate the fragment from placebo at all.
So the span on this page records what was tried. It is not a scale to climb. Reading the top of it as a target reads the evidence backwards, and that is the specific error this compound invites.
One vial size, two water volumes, and a milligram-scale draw that sits high on the barrel either way. Rounding error is not this page’s problem.
What the number means is. On a few compounds here the arithmetic is entirely comfortable while the evidence behind the input is the weakest part of the page. This is one of them.
AOD-9604 is not short of human study. It is short of readable human study. A company ran controlled obesity trials and never wrote them up as papers. So the quantities on this page arrive through a review of a market announcement.
The chain runs from trial, to company announcement, to review, to record. Each link is a place a detail can be lost. Nothing at the far end can be checked against the near end.
One row is a trial arm. It was swallowed, once a day, across a course of weeks. The other row is what circulates now: a much smaller daily amount, split across injections under the skin.
The fragment exists because of an idea. Researchers cut the tail off growth hormone believing the fat-mobilizing activity sat there, and that the growth and glucose effects belonged to the rest.
This fragment has an odd afterlife. It failed as a drug candidate, then turned up as a food and supplement ingredient. It later became publicly contentious in an Australian sports-supplements investigation.
Most compounds get their vial ladder from somebody filling for a course. Nothing fills this one. Development stopped, no approved product exists, and no pharmacy dispenses a strength for it.
Mix 5 mg into 3 mL and one U-100 unit carries 16.7 mcg. The table shows how much peptide is in each numbered syringe line. These are conversion examples, not suggested doses.
| U-100 line | Volume | Mass (mcg) | Mass (mg) |
|---|---|---|---|
| 10 u | 0.10 mL | 167 mcg | 0.167 mg |
| 20 u | 0.20 mL | 333 mcg | 0.333 mg |
| 30 u | 0.30 mL | 500 mcg | 0.5 mg |
| 40 u | 0.40 mL | 667 mcg | 0.667 mg |
| 50 u | 0.50 mL | 833 mcg | 0.833 mg |
| 60 u | 0.60 mL | 1,000 mcg | 1 mg |
| 70 u | 0.70 mL | 1,167 mcg | 1.167 mg |
| 80 u | 0.80 mL | 1,333 mcg | 1.333 mg |
| 90 u | 0.90 mL | 1,500 mcg | 1.5 mg |
| 100 u | 1.00 mL | 1,667 mcg | 1.667 mg |
The math is only one part of the question. These guides cover the compound, published doses, side effects, mixing steps and supplies.
AOD-9604 without an approved label: what exists instead
AOD-9604 dosing evidence, without an approved schedule
Which AOD-9604 reactions warrant medical attention
What the AOD-9604 draw needs from buying the mixing water
Bacteriostatic water before the AOD-9604 arithmetic starts
Choosing the Hospira vial for an AOD-9604 draw